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Abstract
Akt is a pro-survival kinase frequently activated in human cancers and
is associated with more aggressive tumors that resist therapy. Here,
we connect Akt pathway activation to reduced sensitivity to
chemotherapy via Akt phosphorylation of Bax at residue S184, one of
the pro-apoptotic Bcl-2 family proteins required for cells to undergo
apoptosis. We show that phosphorylation by Akt converts the pro-
apoptotic protein Bax into an anti-apoptotic protein. Mechanistically,
we show that phosphorylation (i) enables Bax binding to pro-apoptotic
BH3 proteins in solution, and (ii) prevents Bax inserting into mitochon-
dria. Together, these alterations promote resistance to apoptotic stim-
uli by sequestering pro-apoptotic activator BH3 proteins. Bax
phosphorylation correlates with cellular resistance to BH3mimetics in
primary ovarian cancer cells. Further, analysis of the TCGA database
reveals that 98% of cancer patients with increased BAX levels also
have an upregulated Akt pathway, compared to 47% of patients with
unchanged or decreased BAX levels. These results suggest that in
patients, increased phosphorylated anti-apoptotic Bax promotes resis-
tance of cancer cells to inherent and drug-induced apoptosis.
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Introduction
Activation of the mitochondrial apoptosis pathway in cancer cells
serves as an important route of cell death following treatment with
chemotherapeutic agents. Alteration of this pathway can cause resis-
tance to therapy in cancer cells. A decisive step for commitment to
apoptosis is mitochondrial outer membrane permeabilization
(MOMP) by the pro-apoptotic Bax and/or Bak proteins that release
intermembrane space proteins including cytochrome c into cytosol
[1,2]. Membrane permeabilization by Bax and Bak is provoked by
activator proteins including the BH3 proteins Bim and Bid. Pro-
survival Bcl-2 proteins (Bcl-2, Bcl-XL, Mcl-1, Bfl-1, and Bcl-W)
inhibit MOMP by sequestering either activator BH3 proteins or Bax
and Bak [3,4]. Other so-called sensitizer BH3 proteins, including
Bad, Noxa, and Bik, cannot activate Bax or Bak, but rather exert a
pro-death function by competing for the BH3 binding sites of pro-
survival proteins [2,5]. Differences in the affinities of the interac-
tions, expression levels, and post-translational modifications of
these proteins together determine the fate of the cell.
Measurement of MOMP upon incubating BH3 domain-derived
peptides with mitochondria and identifying differential response
patterns was successfully translated into an assay called BH3 profiling
[6,7]. By interpreting the pattern of mitochondrial sensitivity to BH3
peptides of different affinities for anti-apoptotic proteins, BH3 profil-
ing can be used to identify dependence on individual anti-apoptotic
Bcl-2 proteins for survival and sensitivity to inhibitors. Certain BH3
domain peptides, including those from Bid and Bim, interact with all
known anti-apoptotic proteins. Mitochondrial sensitivity to these
peptides can be interpreted as a measure of how close a cell is to the
threshold of apoptosis, or how “primed” a cell is for death [6,8]. The
degree of priming predicts how sensitive the cell will be to toxic
insults, and correlates with clinical response to chemotherapy [9].
In cancer, particularly in breast cancer, upregulation of the Akt
pathway is strongly associated with poor prognosis and resistance to
therapy [10]. PTEN (phosphatase and tensin homolog deleted on chro-
mosome 10) functions as a lipid phosphatase to restrain Akt pathway
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activation by diminishing the phosphatidylinositol-3,4,5-biphosphate
(PIP3) cellular pool through hydrolysis of 3-phosphate on PIP3 to
generate phosphatidylinositol-4,5-biphosphate (PIP2). PI3Ks phospho-
rylate PIP2 to regenerate PIP3 which promotes Akt recruitment to
plasma membrane through binding its pleckstrin-homology (PH)
domain. Following recruitment to the plasma membrane by PIP3, Akt
is phosphorylated by PDK1 at T308 and by mTORC2 at S473 which
leads to its activation [11]. Hence, inactivation or loss of PTEN results
in increased accumulation of PIP3 and constitutively active Akt signal-
ing which promotes cell growth and survival. The Akt pathway regu-
lates fundamental processes in cells, including survival, cell cycle
progression, and metabolism. Upregulation of the Akt signaling path-
way is commonly detected in a wide spectrum of human cancers.
Several mechanisms including genomic amplification of Akt or growth
factor receptors, PTEN deletion or mutations, or activating mutations
in pathway genes can activate Akt in cancer cells.
Importantly, Akt blocks pro-death signaling upstream of MOMP
[12]. However, it is still unclear how pro-survival Akt signaling
makes the critical connection to the Bcl-2 family that controls the
mitochondrial apoptosis pathway. Some suggest an indirect effect,
for instance, via transcriptional control of pro-apoptotic Bcl-2 family
proteins via the FOXO family of transcriptional regulators [11]. Akt
could also play a more direct role since it can phosphorylate the
pro-apoptotic BH3 protein Bad. However, Bad is dispensable for
apoptosis induced by several mechanisms [13,14], suggesting that a
more central Bcl-2 family protein such as Bax might also be
controlled by AKT [15,16]. However, reports on the function of
phosphorylated Bax are inconsistent—one suggests that S184 phos-
phorylation activates Bax [17], while others suggest that S184-phos-
phorylated Bax is inhibited [15,16,18,19].
Here, we show that Akt directly phosphorylates Bax and can local-
ize to mitochondria. Unexpectedly, phosphorylation switches the
function of Bax from pro- to anti-apoptotic, thereby impeding mito-
chondrial priming for apoptosis. Mechanistically, we show (i) that
phosphorylation of Bax blocks its insertion into membranes upstream
of the oligomerization essential for its pro-apoptotic membrane
permeabilization function, and (ii) that after phosphorylation, Bax
acts as a dominant negative by binding to and sequestering activator
BH3 proteins thereby inhibiting BH3-protein-mediated apoptosis.
Consistent with a role for this switch in Bax function in human
disease, we find that in cancer patients with elevated Bax, Bax expres-
sion is positively associated with an increase in expression of genes
in the Akt pathway. Our data suggest that in cancers with upregulated
Akt pathway signaling, one means of inhibiting apoptosis is to select
for increased levels of Bax which is then phosphorylated switching
on its anti-apoptotic function. Given the established role of Bax as a
critical effector of MOMP downstream of many pro-apoptotic signals,
phosphorylation of Bax is likely a key mediator of the anti-apoptotic
effect exerted by upregulated Akt in cancer.
Results
A post-translational modification alters mitochondrial priming in
ABT-737-resistant cell lines
BH3 profiling with Bad can predict cellular sensitivity to Bcl-2 antag-
onism by ABT-737 [6,8,20]. To extend this observation, we tested
this correlation in a new cancer cell line panel. As shown in Fig 1A,
we found that mitochondria from MDA-MB-435, MDA-MB-468,
SF539, and 768-O cells were at least as sensitive to Bad as MCF-7,
T47-D, or ZR-75-1 cell lines. Surprisingly, mitochondrial sensitivity
was not predictive of cellular responses as only MDA-MB-435 cells
were sensitive to ABT-737 (EC50, 32 nM), and other cells were rela-
tively insensitive to ABT-737 with EC50 values at micromolar levels
(Fig 1B).
One possible explanation for the deviation from sensitivity
predicted by BH3 profiling is that post-translational modifications
(PTMs) are present in cells that are not present in our in vitro
system. Since the primary post-translational modification of Bcl-2
family proteins is phosphorylation [21,22], we tested whether
including phosphatase inhibitors in mitochondrial isolation buffer
and during BH3 profiling in experimental buffer would modulate
the priming profile (Fig 1C). We found that phosphatase inhibitors
significantly reduced sensitivity to BH3 peptides in ABT-737-resis-
tant cells (MDA-MB-468 and ZR-75-1) but had no significant effect
on BH3 peptide response in ABT-737-sensitive cells (MDA-MB-435
and MCF-7). Taken together, our results suggest that a kinase is
unpriming mitochondria selectively in the ABT-737-resistant cell
lines. For this reason, we used a phosphatase inhibitor cocktail in
all subsequent BH3 profiling experiments.
Bax is phosphorylated in ABT-737-resistant cell lines
Resistance to the BH3 mimetic ABT-199 is reportedly overcome by
inhibition of the Akt pathway [23]. Furthermore, since Bax can be
phosphorylated by Akt at residue S184 and inhibited [15,16], we
examined the phosphorylation status of Bax in ABT-737-resistant
cells. Immunoprecipitating Bax and blotting for phosphoserine
suggest Bax is phosphorylated, while blotting with a phospho-Bax
S184 antibody demonstrated that residue S184 is phosphorylated in
ABT-737-resistant MDA-MB-468 cells, but not in ABT-737-sensitive
MDA-MB-435 cells (Figs 2A and EV1A).
Bax can be phosphorylated at multiple residues [21]. To further
confirm the specific phosphorylation of Bax on residue S184 in the
ABT-737-resistant MDA-MB-468 cells, we created a mutant Bax
(S184A) that would prevent Bax phosphorylation at residue S184. In
ABT-737-resistant MDA-MB-468 cells, GFP immunoprecipitation
revealed that GFP-Bax was phosphorylated at residue S184, whereas
GFP-Bax S184A was not (Figs 2B and EV1B). These data support
S184 as a primary phosphorylation site on Bax in the ABT-737-resis-
tant cells and corroborate other studies that also observed Bax S184
phosphorylation by Akt [15,16,19,24].
While Bax is localized both in the cytosol and at mitochondria of
many cells, migration to the mitochondrion is essential for Bax pro-
apoptotic function. We evaluated the subcellular localization of
GFP-tagged WT Bax and the S184A (phosphorylation-resistant) and
S184E (phosphomimetic) mutants in ABT-737-resistant MDA-MB-
468 cells. GFP-Bax was localized diffusely throughout the cell and
also co-localized with mitochondria, while GFP-Bax S184A showed
punctate, mostly mitochondrial localization (Fig 2C). In contrast,
GFP-Bax S184E showed a diffuse cytoplasmic and nuclear pattern
without mitochondrial localization (Fig 2C). These data were con-
firmed by subcellular fractionation, where GFP-Bax S184A is
predominantly mitochondrial, GFP-Bax S184E is cytosolic and
nuclear, and GFP-Bax levels are similar in all fractions (Fig EV1C).
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In transient transfection experiments, both GFP-Bax and GFP-
Bax S184A were highly toxic to MDA-MB-468 cells. Spontaneous
cell death was also increased in cells stably expressing these
constructs (Fig 2D), whereas there was minimal basal cell death in
GFP-Bax S184E-expressing cells. Consistent with these results, GFP-
Bax- and GFP-Bax S184A-expressing MDA-MB-468 cells were signifi-
cantly more sensitive to ABT-737 treatment. By contrast, cells
expressing GFP-Bax S184E remained resistant to ABT-737 (Fig 2D).
Akt phosphorylates Bax in ABT-737-resistant cells
Since Bax can be phosphorylated at residue S184 by Akt, this path-
way may mediate the resistance to ABT-737 we observed in cancer
cells (Fig 1B). To test this hypothesis, we examined the effect of
small molecule inhibitors of the Akt pathway on mitochondrial
priming. As predicted, treatment of ABT-737-resistant MDA-MB-
468 cells (Fig 3A, top left panel) or ZR-75-1 cells (Fig 3A, bottom
left panel) with Akt pathway inhibitors significantly enhanced
priming in the majority of cases as shown by increased response
to BH3 peptides (Appendix Table S1). As expected, there was no
significant difference in the priming of ABT-737-sensitive MDA-
MB-435 cells (Fig 3A, top right panel) or MCF-7 cells (Fig 3A,
bottom right panel) when treated with Akt pathway inhibitors
(Appendix Table S1). Furthermore, Bax phosphorylation at S184 is
substantially reduced when the ABT-737-resistant cell lines, MDA-
MB-468 and ZR-75-1, are treated with AKT pathway inhibitors
A
C
B
Figure 1. A post-translational modification alters priming of mitochondria from cancer cell lines.
A Mitochondria isolated from the indicated cell lines were incubated with Bad peptide and MOMP measured as % cytochrome c release determined by ELISA. Bars
indicate the mean of three independent experiments (n = 3). Symbols indicate the mean of at least two technical replicates for each independent experiment.
B Cells were treated with indicated concentrations of ABT-737 for 48 h. ABT-737 EC50 values of cancer cell lines were determined by using MTT assay (mean  SEM,
n = 4 experimental replicates).
C Mitochondria isolated from the indicated cell lines were incubated with the indicated BH3 peptides in the presence or absence of phosphatase inhibitor cocktail
PhosSTOP in all buffers. MOMP was measured as % cytochrome c release determined by ELISA. Bars indicate the mean of three independent experiments (n = 3).
Symbols indicate the mean of at least two technical replicates for each independent experiment. One-way ANOVA was used followed by post hoc t-tests with
Bonferroni correction for multiple comparisons (ns = not significant). MDA-MB-468 (Bim ****P < 0.0001; Bad **P = 0.0059; BMF ***P = 0.0002). ZR-75-1 (Bid
***P = 0.0003; Bim ****P < 0.0001; Bad **P = 0.0041; Puma ***P = 0.0007).
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(Figs 3B and EV2A), directly linking Akt activation to Bax S184
phosphorylation.
To test whether Akt directly alters mitochondrial priming,
cytosolic (S100) fractions from ABT-737-resistant MDA-MB-468 cells
(Figs 3C and EV2B) or ZR-75-1 cells (Fig EV2B) were isolated and
pre-incubated with mitochondria isolated from ABT-737-sensitive
MDA-MB-435 cells before BH3 profiling experiments. This pre-incu-
bation led to decreased priming of MDA-MB-435 mitochondria, with
◀ Figure 2. Bax is phosphorylated in ABT-737-resistant cell lines.A Top two panels: Phosphorylation of Bax was evaluated using lysates from MDA-MB-435 and MDA-MB-468 cells by Western blotting with the indicated antibodies (IB)
after immunoprecipitation with the indicated antibodies (IP). Lower two panels: 5–10% of the total lysates (input) were probed for Bax (Bax Δ21 antibody) and actin
as expression and loading controls, respectively, by Western blotting with the indicated antibodies (IB).
B Phosphorylation of Bax was evaluated using lysates from GFP-Bax- and GFP-Bax S184A-expressing MDA-MB-468 cells by blotting with the antibodies indicated at
the right after precipitation with the antibodies indicated below the panels. Lysates from untransfected cells (MDA-MB-468 WT) and IgG IP are used as negative
controls. Lower panels: 5–10% of the total lysates were probed for GFP and actin as expression and loading controls, respectively. Asterisk (*) indicates a cross-
reacting band. Bax delta-21 antibody was used for IB of Bax.
C MDA-MB-468 cells were transfected with plasmids encoding GFP-Bax, GFP-Bax S184A, or GFP-Bax S184E, and the localization of Bax was evaluated by confocal
microscopy (upper panel). Cells were co-stained with MitoTracker Red CMXRos (mitochondria) and DAPI (nucleus). Whole-image Pearson’s correlation coefficients
between MitoTracker and GFP for the single images shown were 0.644, 0.607, and 0.206 for GFP-Bax, GFP-Bax S184A, and GFP-Bax S184E, respectively (see
Appendix Fig S1). Scale bars: 20 lm.
D MDA-MB-468 cells that were either untransfected or expressing GFP, GFP-Bax, GFP-Bax S184A, or GFP-Bax S184E were treated with ABT-737 (100 nM, 48 h), and
apoptosis was evaluated by Annexin V staining followed by fluorescence-activated cell sorting (FACS). Bars indicate the mean of three independent experiments
(n = 3). Symbols indicate the mean of at least two technical replicates for each independent experiment. One-way ANOVA was used followed by post hoc t-tests with
Bonferroni correction (****P < 0.001, ns = not significant).
Data information: See also Fig EV1.
▸Figure 3. AKT phosphorylates and inhibits Bax, preventing mitochondrial cytochrome c release in response to BH3 peptides and proteins.A BH3-peptide-resistant (left panels; MDA-MB-468 and ZR-75-1) and BH3-peptide-sensitive (right panels; MDA-MB-435 and MCF-7) cells were treated with direct Akt
inhibitors (MK-2206 [1 lM], A-443654 [0.4 lM]) or Akt pathway inhibitors (LY294002 [25 lM], deguelin [10 nM]) for 6 h, and BH3 profiles were analyzed. The
phosphatase inhibitor cocktail PhosSTOP was used in all buffers for these experiments. Cytochrome c release was determined by ELISA. Bars indicate the mean of
three independent experiments (n = 3). Symbols indicate the mean of at least two technical replicates for each independent experiment. Two-way ANOVA was
conducted on the influence of two independent variables (BH3 peptide, drug) on cytochrome c release of isolated mitochondria for each cell line followed by post hoc
t-tests with Bonferroni correction for multiple comparisons. Each drug treatment was statistically compared to DMSO control within each peptide treatment group.
The percentage of P-values that were significant (DMSO control to each drug) was 65% for MDA-MB-468, 0% for MDA-MB-435, 95% for ZR-75-1, and 0% for MDA-
MB-435. See Appendix Table S1 for P-values of each comparison.
B Top two panels: MDA-MB-468 and ZR-75-1 cells were treated with 1 lM MK-2206, 0.4 lM A-443654, 25 lM LY294002, or 10 nM deguelin where indicated.
Phosphorylation of Bax was evaluated using lysates from the treated cells by Western blotting with the indicated antibodies (IB) after immunoprecipitation with the
indicated antibodies (IP). Lower two panels: 5%–10% of the total lysates (input) were probed for Bax and actin as expression and loading controls, respectively, by
Western blotting with the indicated antibodies (IB). Bax Δ21 antibody was used for both IP and IB of Bax.
C S100 fractions from untreated cells (MDA-MB-468) or from cells treated with direct Akt inhibitors (MK-2206 [1 lM], A-443654 [0.4 lM]) or Akt pathway inhibitors
(LY294002 [25 lM], deguelin [10 nM]) were isolated. Akt was immunodepleted by sequential immunoprecipitation of untreated S100 fractions, and the efficiency of
immunodepletion was tested by immunoblot analysis. IgG was used as a negative control for immunodepletion experiments (inset). Indicated S100 fractions were
incubated with MDA-MB-435 mitochondrial preparations, and the resulting extent of priming was assessed by measuring the cytochrome c released from MDA-MB-
435 mitochondria by Bid BH3 peptide (treatments with Bim, Bad, Puma, and Bmf are located in Fig EV2B). Cytochrome c release was determined by ELISA. The
phosphatase inhibitor cocktail PhosSTOP was used in all buffers for these experiments. Bars indicate the mean of three independent experiments (n = 3). Symbols
indicate the mean of at least two technical replicates for each independent experiment. Two-way ANOVA was conducted on the influence of two independent
variables (BH3 peptide, conditions) on cytochrome c release of isolated mitochondria followed by post hoc t-tests with Bonferroni correction for multiple comparisons.
Each condition was statistically compared to control (white bar) within each peptide treatment group. Shown here are P-values for treatment with Bid BH3 peptide
(ns = not significant). MDA-MB-468 S100 (**P = 0.0031), A443654-pre-treated MDA-MB-468 S100 (*P = 0.0324), and IgG-pre-treated MDA-MB-468 S100
(*P = 0.0432). See Appendix Table S2 for P-values.
D MDA-MB-435 mitochondria were incubated with recombinant active Akt in kinase assay buffer containing ATP, and alteration of priming in MDA-MB-435
mitochondria was detected by using BH3 profiling. Cytochrome c release was determined by ELISA. The phosphatase inhibitor cocktail PhosSTOP was used in all
buffers for these experiments. Bars indicate the mean of three independent experiments (n = 3). Symbols indicate the mean of at least two technical replicates for
each independent experiment. Two-way ANOVA was conducted on the influence of two independent variables (BH3 peptide, treatment) on cytochrome c release. BH3
peptides included Bid, Bim, Bad, Puma, and Bmf. Treatment included Akt or buffer alone. Each drug treatment was statistically compared to control (white bar)
within each peptide group using t-tests with Bonferroni correction for multiple comparisons (ns = not significant). Bid, Akt (*P = 0.0283); Bim, Akt (*P = 0.0482);
Puma, Akt (*P = 0.0170); Bmf, Akt (**P = 0.0035).
E tBid (5 nM) and Bax (50 nM), with or without active Akt plus ATP, were incubated with mitochondria isolated from Bax/ Bak/ DKO MEFs for 1 h, and
mitochondrial cytochrome c release was determined by ELISA. Bars indicate the mean of three independent experiments (n = 3). Symbols indicate the mean of at
least two technical replicates for each independent experiment.
F tBid, Bax, Akt, ATP, and the Akt inhibitor MK-2206, as indicated, were incubated with mitochondria isolated from Bax/ Bak/ DKO MEFs for 1 h, and mitochondrial
cytochrome c release was determined by ELISA. The shaded and circled reagents were pre-incubated before the addition of the other indicated reagents. Bars indicate
the mean of three independent experiments (n = 3). Symbols indicate the mean of at least two technical replicates for each independent experiment.
G tBid (5 nM) and Bax S184A (50 nM), with or without active Akt plus ATP, were incubated with mitochondria isolated from Bax/ Bak/ DKO MEFs for 1 h, and
mitochondrial cytochrome c release was determined by ELISA. Bars indicate the mean of three independent experiments (n = 3). Symbols indicate the mean of at
least two technical replicates for each independent experiment.
Data information: See also Fig EV2.
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decreased cytochrome c release in response to Bid and other BH3
peptides (Figs 3C and EV2B). Pre-treatment of ABT-737-resistant
cells with Akt pathway inhibitors or immunodepletion of Akt from
the S100 fraction abrogated inhibition of priming by the S100 frac-
tion (Figs 3C and EV2B). In general across all peptides, when
compared to control, treatment of MDA-MB-435 mitochondria with
the S100 fraction or IgG-pre-treated S100 fraction from either MDA-
MB-468 or ZR-75-1 cells was associated with a significant decrease
in priming, whereas most other treatments resulted in non-signifi-
cant changes in the level of priming (Appendix Table S2). Incuba-
tion of isolated MDA-MB-435 mitochondria with active recombinant
Akt unprimes mitochondria resulting in a significant decrease in
cytochrome c release mediated by BH3 peptides (Fig 3D). Thus,
only when Akt was present and active, BH3-peptide-mediated cyto-
chrome c release was inhibited. Additionally, Akt is localized to
both the cytosol and mitochondria in ABT-737-resistant MDA-MB-
468 and ZR-75-1 cells, but mostly in the cytosol of ABT-737-sensi-
tive MDA-MB 435 and MCF-7 cells (Fig EV2C). Treatment with the
inhibitors of Akt signaling, deguelin, LY294002, and MK-2206,
prevented Akt from localizing to mitochondria of MDA-MB-468 or
ZR-75-1 cells but did not alter Akt localization in MDA-MB 435 or
MCF-7 cells (Fig EV2C). In contrast, A-443654 promoted Akt local-
ization to mitochondria; however, this drug is known to promote
paradoxical Akt phosphorylation, indicative of active Akt, with
concomitant Akt kinase inhibition (Fig EV2C) [25,26]. A fraction of
endogenous Bax was localized to the mitochondria in MDA-MB-435
cells where Bax was primarily cytosolic, suggesting that Akt can act
on Bax in these experiments (Fig EV2D). Taken together, our results
indicate a potent effect of Akt to prevent priming of mitochondria,
likely through the phosphorylation of Bax.
To test Akt-mediated Bax inhibition in a well-defined model
system, we reconstituted Bax-regulated MOMP using mitochondria
from Bax/ Bak/ DKO MEFs (Bax and Bak knockout was con-
firmed by Western blots; Fig EV2E). Incubation of Bax and Akt
results in phosphorylation of Bax (Fig EV2F). Consistent with
these results, combining tBid and Bax treatments triggered cyto-
chrome c release from mitochondria that was substantially
inhibited when tBid and Bax were incubated with active Akt
(Fig 3E). Further, excluding ATP from the reaction eliminated the
protective effect of Akt, while adding ATP alone to tBid/Bax did
not have any impact on mitochondrial permeabilization
(Fig EV2G). Adding the Akt inhibitor MK-2206 to a kinase assay
reaction composed of Akt, ATP, tBid, and Bax attenuated the inhi-
bitory effect of Akt on cytochrome c release, confirming that Akt
kinase activity is required for inhibition of tBid/Bax-mediated
mitochondrial permeabilization (Fig 3F). Pre-incubating Bax, but
not tBid, with active Akt plus ATP before exposing them to mito-
chondria decreased cytochrome c release considerably, whereas
pre-incubation of Akt, ATP, and MK-2206 prevented Akt-mediated
inhibition of tBid/Bax-mediated cytochrome c release (Fig 3F).
Incubating Akt with Bax S184A had no effect on tBid/Bax-
mediated cytochrome c release, showing that Bax S184 phosphory-
lation by Akt, rather than phosphorylation of an unknown protein
by Akt at the mitochondria, is responsible for inhibition of MOMP
(Fig 3G).
Phosphomimetic Bax can bind cBid, but does not insert helices 5
and 9 into the membrane inhibiting pore formation
We examined how Bax phosphorylation at S184 affects Bax-
mediated membrane permeabilization using a phosphomimetic
mutant of Bax (S184E). This mutant was used to ensure that all of
the Bax functioned as a phosphorylated protein because in vitro Akt
phosphorylation of recombinant Bax was incomplete (data not
shown). We also assessed whether a phosphorylation-resistant
mutant of Bax (S184A) alters the activation mechanism of Bax.
When transitioning from a soluble monomer to a membrane-
embedded oligomer, Bax undergoes sequential activation steps
(Fig 4A) that can be examined using fluorescence spectroscopy with
purified proteins [27,28]. The sequence begins with recruitment of
Bax to the membrane by interaction with an activator BH3 protein
on the membrane surface. Bax then inserts helices 5, 6, and 9 into
the membrane followed by oligomerization and membrane perme-
abilization (Fig 4A).
▸Figure 4. Phosphomimetic Bax can bind cBid, but cannot insert helices 5 and 9 into the membrane abrogating pore formation.A Schematic of the activation mechanism of Bax. Caspase-8 cleaved Bid (cBid) spontaneously targets to and embeds within the lipid bilayer. Here, the amino-terminal
portion of cBid dissociates and the carboxy-terminal portion becomes tBid (truncated Bid) [56]. Soluble Bax interacts with tBid at the membrane (tested in panel B).
This interaction activates Bax and allows Bax to insert alpha-helices 5, 6, and 9 into the bilayer (tested in panel C). After insertion of Bax within the lipid bilayer, Bax
oligomerizes and permeabilizes the membrane (tested in panels D and E, respectively).
B The apparent affinity between cBid and Bax (step 1) was measured with liposomes and in solution using FRET. Samples containing liposomes were incubated with
20 nM cBid 126C-DAC, and Bax-NBD was added as indicated. FRET efficiency was calculated at 2-h endpoint. Symbols indicate the mean of at least two technical
replicates for each independent experiment (n = 3). These data were fit to an equation that describes the equilibrium binding between two proteins (lines; see
Materials and Methods).
C Insertion of alpha-helices 5 and 9 of Bax into the liposome bilayer (step 2) was measured using the environment-sensitive dye NBD covalently attached to cysteine
residues at the indicated locations in Bax. The relative change of NBD emission (F/F0) was calculated at a 1-h endpoint with 20 nM cBid (cBid) or buffer as a control
(buffer) in the presence of liposomes. Bars indicate the mean of three independent experiments (n = 3). Symbols indicate the mean of at least two technical
replicates for each independent experiment. The red dotted line indicates no change in fluorescence (F/F0 = 1).
D Bax oligomerization (step 3) was measured by FRET between Bax monomers. Samples containing liposomes were incubated with 10 nM DAC (donor)-labeled WT or
S184E Bax and 100 nM of NBD (acceptor)-labeled WT or S184E Bax in the absence (buffer) or presence of 20 nM cBid. FRET efficiency was calculated at 2-h
endpoint. Bars indicate the mean of three independent experiments (n = 3). Symbols indicate the mean of at least two technical replicates for each independent
experiment.
E The liposome permeabilization activity of Bax was measured using an ANTS/DPX release assay. ANTS/DPX liposomes were incubated with 100 nM of the indicated
Bax in the absence (buffer) or presence of 20 nM cBid. Liposomes indicates a control reaction without added Bax. Bars indicate the mean of three independent
experiments (n = 3). Symbols indicate the mean of at least two technical replicates for each independent experiment.
Data information: See also Fig EV3.
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To assess how phosphorylation at S184 affects the first step, the
interaction between cBid and Bax was measured using fluorescence
resonance energy transfer (FRET) for the proteins labeled with the
dyes DAC and NBD as the donor and acceptor [28]. As expected,
WT Bax and Bax S184A bound to cBid only in the presence of
membranes (Figs 4B and EV3A). Unexpectedly, Bax S184E bound to
both cBid (Fig 4B) and Bim (Fig EV3B). Furthermore, WT Bax and
Bax S184E bound cBid with similar affinities (30 and 33 nM, respec-
tively). Unlike WT Bax, Bax S184E also bound cBid in solution.
As Bax S184E binds cBid and Bim, we determined whether it
was impaired for insertion into the lipid bilayer. To examine the
insertion of specific residues of Bax into membranes, the residue to
be probed was exchanged for a cysteine in an otherwise cysteine-
less Bax and the mutant protein was labeled with an iodoac-
etamide–NBD dye. Positioning the environment-sensitive NBD dye
on cysteines located at either residue 126 in helix 5 or residue 175
in helix 9 enabled detection of the transition of the labeled region of
the protein into the lipid bilayer by monitoring the resulting increase
in NBD fluorescence. Upon activation of Bax by cBid, residues 126
and 175 of Bax become protected from chemical labeling in cell
lysates, suggesting that in cells, they insert into the mitochondrial
outer membrane (MOM) [29]. Thus, we interpret the increase in
NBD emission of Bax labeled at residues 126C and 175C as the
insertion of these residues of Bax into membranes. In response to
the addition of cBid to NBD-labeled Bax and liposomes, the fluores-
cence of NBD at either location increased, confirming that these resi-
dues of helices 5 and 9 insert into membranes (Fig 4C). In contrast,
NBD-labeled phosphomimetic Bax did not insert either residue into
liposome membranes since the fluorescence emission from NBD
probes at 126C and 175C did not increase substantially. Consistent
with previous reports and the localization data above, residues 126
and 175 of the control protein Bax S184A spontaneously inserted
into the membrane in the absence of cBid (Fig EV3C). These data
indicate that insertion of Bax into membranes is inhibited by phos-
phorylation of Bax S184.
Because phosphomimetic Bax bound to cBid in solution, it is
possible that cBid triggers phosphomimetic Bax oligomerization in
the absence of Bax helix 5 and 9 insertion into membranes. To
measure Bax oligomerization by FRET, Bax molecules labeled with
either the donor or acceptor dye were incubated with liposomes. As
expected, after incubation with cBid, FRET was detected between
Bax proteins (Fig 4D) and Bax S184A (Fig EV3D). However, FRET
was not detected for Bax S184E or between Bax and Bax S184E,
supporting that phosphorylation prevents the upstream step Bax
insertion into membranes, therefore also inhibiting Bax oligomeriza-
tion (Fig 4D).
To corroborate our results suggesting that Bax S184E does not
insert into membranes, we assessed membrane permeabilization by
Bax S184E compared to WT Bax. To test this final step in Bax activa-
tion, we used a dye release assay in which permeabilization of lipo-
somes releases both the entrapped dye ANTS and its quencher DPX.
Release from liposomes dilutes both species resulting in a dramatic
increase in the ANTS fluorescence. Compared to the wild-type
protein, the phosphomimetic S184E mutation greatly attenuated
ANTS release from liposomes in response to cBid (Fig 4E). This
assay was also used in control experiments to confirm that
neither the S184A point mutation, labeling with the fluorescent
dyes, nor single cysteine mutations (required for NBD or DAC
labeling) altered the membrane permeabilizing function of Bax
(Fig EV3E).
Phosphorylation of Bax at residue 184 converts Bax into an
anti-apoptotic protein protecting cells from death stimuli in
the cytoplasm
Anti-apoptotic proteins have two modes of inhibition of MOMP
[30]. Mode 1 inhibition occurs when anti-apoptotic proteins
sequester BH3 proteins, thus preventing BH3-mediated activation of
Bax. Mode 2 inhibition occurs when anti-apoptotic proteins bind to
active Bax and Bak, thus inhibiting their oligomerization. Both
modes result in inhibition of MOMP and subsequent cell death. Bax
S184E is blocked at insertion into membranes but can bind BH3 acti-
vator proteins, suggesting that phosphomimetic Bax could inhibit
MOMP by sequestering BH3 proteins. Consistent with this hypothe-
sis, phosphomimetic Bax reduced liposome permeabilization by WT
Bax and cBid or Bim in a dose-dependent manner as shown by a
decrease in ANTS and DPX release (Fig 5A), whereas incubation
with Bax S184A had the opposite effect (Fig EV4A). Thus, in
contrast to previous studies suggesting phosphorylation of Bax abro-
gates function, Bax S184E functions to impair liposome permeabi-
lization by sequestering BH3 proteins.
If our in vitro results translate to cells, phosphorylation of Bax
may be sufficient to protect cells from apoptotic stimuli. To test this,
Bax S184E or the control Bax S184A was stably expressed in cells
with a fluorescence protein tag mCerulean3 (mC3) to enable moni-
toring expression of the mutant in WT or Bax//Bak/ DKO
BMK. Expression of each construct and confirmation of Bax and Bak
expression or lack thereof in WT and Bax//Bak/ DKO BMK
cells was confirmed by Western blot (Fig EV4B). Stable Bax-S184E
expression in WT BMK cells, which have endogenous expression of
Bax and Bak, had a significant protective effect against cell death
induced by the pro-death cytokine TNF-a and cycloheximide, the
pan-kinase inhibitor staurosporine, and the HDAC inhibitor panobi-
nostat (Figs 5B and EV4C). In BMK cells, apoptosis was dependent
on endogenous WT Bax and Bak since Bax/ Bak/ double-
knockout (DKO) BMK cells did not die from exposure to low
concentrations of these agents. The control cell lines stably express-
ing Bax S184A had a marked increase in apoptosis in response to
each drug, whereas Bax//Bak/ DKO BMK cells stably express-
ing Bax S184E were refractory to apoptosis. These data suggest that
sequestration of BH3 proteins by Bax S184E likely inhibits both Bax
and Bak-induced MOMP. That some STS-treated BMK cells and
DKO BMK cells expressing Bax S184E died suggests that this drug
may also activate Bax independently of BH3 protein binding. In
these experiments, exogenous Bax S184E protein levels were similar
to those of endogenous Bax (Fig EV4B). Moreover, expression of
Bax S184E in WT BMK cells did not alter the levels of endogenous
Bax and resulted in a small increase in Bak. Thus, the decrease in
apoptosis due to expression of Bax S184E was not due to decreased
endogenous Bax or Bak compared to WT cells, nor was the decrease
in apoptosis due an artifact of transfection since Bax S184A expres-
sion in the WT BMK cells resulted in enhanced apoptosis.
Bax S184E binds activator BH3 proteins in solution (Fig 4B) and
has a mainly cytoplasmic localization in MDA-MB-468 cells (Figs 2C
and EV1C), suggesting that phosphomimetic Bax sequesters activa-
tor BH3 proteins in the cytosol thereby preventing apoptosis. To test
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whether Bax S184E remains in the cytoplasm under cell death
conditions, we compared the co-localization of mCerulean3-Bax
proteins to that of MitoTracker Red (Fig 5C and D) and the localiza-
tion pattern of mCerulean3-Bax proteins in the presence and
absence of STS (Fig EV4D and E). In addition to STS, cells were
treated with a caspase inhibitor in order to delay the later stages of
apoptosis for optimal imaging of mCerulean3-fused WT Bax, Bax
S184E, or Bax S184A. MitoTracker Green, a positive control for co-
localization, had a Pearson’s correlation coefficient close to 1,
indicating a near-perfect correlation between two dyes that stain
mitochondria which did not significantly change in response to STS.
Both WT Bax and Bax S184E had a significantly increased co-
localization with MitoTracker Red in response to STS, whereas there
was no significant change in Bax S184A mitochondrial localization
in response to STS (Fig 5D). Additionally, in response to apoptotic
stimuli, Bax localizes to mitochondria resulting in a punctate pattern
of mCerulean3 fluorescence (Fig EV4D). This is most clearly seen
when the proportion of cells with a punctate localization pattern for
A B
C D
Figure 5.
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mCerulean3 was quantified (Fig EV4E). The localization pattern of
mC3-fused WT Bax and Bax S184A transitions from a diffuse to
punctate pattern in response to STS in a dose-dependent manner,
whereas the majority of mC3-fused Bax S184E remains diffuse under
the same conditions (Fig EV4E and D). These data indicate that in
response to STS, Bax S184A remains localized to the mitochondria
but both Bax and Bax S184E transition from the cytoplasm to the
mitochondria where compared to Bax a smaller fraction of Bax
S184E localizes to the mitochondria under apoptotic conditions.
Taken together, the results strongly suggest that phosphorylation of
Bax at position 184 generates a protein that competes with WT Bax
for binding to activator BH3 proteins in a manner analogous to
mode 1, but not mode 2, inhibition of apoptosis by multidomain
anti-apoptotic proteins since phosphorylated Bax only sequesters
BH3 proteins but not other Bax molecules [30,31]. Furthermore, we
predict that sequestration of activator BH3 proteins by phosphory-
lated Bax occurs primarily in the cytosol allowing interception of
activator BH3 proteins diffusing to the MOM before they activate
WT Bax and Bak [28]. However, it appears that Bax S184E can also
sequester BH3 proteins at the mitochondria since Bax S184E also
localizes to mitochondria in response to apoptotic stimuli.
In human cancer, pBax S184 status is correlated with cellular
response to ABT-737 and overexpression of Bax is countered by
Akt pathway activation
The Akt pathway is frequently upregulated in cancers [32], and we
have shown that Akt phosphorylates Bax at position S184 convert-
ing Bax into an anti-apoptotic protein. Although Bax is generally
considered an anti-oncogene and reduced expression is associated
with poor prognosis [33,34], we hypothesized that certain cancers
may be protected from apoptosis due to an increase in the amount
of phosphorylated Bax. To address this hypothesis directly, we
assayed whether ovarian cancer cells isolated from patients had any
correlation between pBax S184 levels and response to chemotherapy
agents (Fig 6A and B). Bax S184 phosphorylation levels were signifi-
cantly correlated (P < 0.05) with resistance to ABT-737 treatment;
however, correlations between Bax S184 phosphorylation and
responses to other chemotherapeutic drugs tested were not statisti-
cally significant (Fig 6B). This may be due to the relatively poor
induction of apoptosis by these drugs and/or because of killing by
both apoptotic and non-apoptotic mechanisms. As expected, pBax
S184 levels were positively correlated with activated Akt (pAkt S473
and pS308) and negatively correlated with PTEN status (Fig EV5A).
As an alternative albeit indirect approach to assess our hypothe-
sis across all cancers, we examined publically available patient data
for gene copy number and mRNA expression data. If, as our results
suggest, Akt is a major enzyme responsible for phosphorylating Bax a
prediction would be that in cancers overexpressing Bax the activity
and/or amount of Akt would be increased. Therefore, gene copy
number alterations (CNA) and mRNA expression data were examined
to determine whether high Bax expression correlates with increased
expression/activation of the Akt pathway genes (AKT1, AKT2,
PIK3CA, PIK3R1) and the Akt pathway inhibitor gene PTEN.
An initial examination of all available CNA data (16,557
samples) from cBioPortal revealed that BAX duplications were
significantly associated with Akt pathway duplications (P < 1010)
as 879/925 (95%) of patients with a BAX duplication also had at a
duplication of at least one Akt pathway gene. In contrast, only 41%
of all samples in the database had Akt pathway gene duplications.
In addition, 183/925 (20%) of patients with BAX duplications had
duplications of three or more Akt pathways genes. Furthermore,
there were deletions in the Akt negative regulator gene PTEN in
11% of patient samples with BAX duplications compared to PTEN
deletions in 17% of all patient samples suggesting a slight but not
statistically significant negative association. However, among the 46
patients with BAX duplications, but no Akt pathway gene duplica-
tions, 13 (28%) had PTEN deletions (P = 0.045). This suggests
◀ Figure 5. Bax S184E protects from apoptotic stimuli and is primarily localized to the cytosol.A Inhibition of liposome permeabilization by phosphomimetic Bax. Liposome permeabilization measured as an increase in fluorescence due to release of ANTS/DPX
from liposomes. Fluorescence was normalized using samples not containing Bax S184E. Samples were incubated with 50 nM WT Bax, 20 nM cBid (black circles), or
Bim (red squares) and the indicated concentration of Bax S184E. Symbols indicate the mean of at least two technical replicates for each independent experiment
(n = 3). These data were fit to a simple exponential decay (lines).
B WT BMK or Bax/ Bak/ DKO BMK cells that are either untransfected or stably expressing the indicated mCerulean3 (mC3) Bax constructs were treated with the
indicated cell death stimuli for 24 h. Cells treated with TNF-alpha were also treated with 5 lg/ml cycloheximide. Cells stained with DRAQ5, Annexin V conjugated
to Alexa 488, and TMRE were imaged on an Opera Phenix automated confocal microscope. Intensity of Annexin V and TMRE staining was measured for > 500 cells
per independent experiment. A threshold was used to automatically determine Annexin V-positive and TMRE-negative cells. Percent apoptosis was calculated by
taking the total number of Annexin V–Alexa 488-positive and TMRE-negative cells and dividing by the total number of cells. Bars indicate the mean of four
independent experiments (n = 4). Symbols indicate the mean of at least two technical replicates (250–500 cells per condition) for each independent experiment.
One-way ANOVA was used, and cell line was statistically compared to WT (white bar) for each drug treatment using t-tests with Bonferroni correction for multiple
comparisons (ns = not significant). TNF-alpha: DKO (***P = 0.0001), WT+mC3-BaxS184A (**P = 0.0031), WT+mC3-BaxS184E (***P = 0.0002), DKO+mC3-BaxS184E
(****P < 0.0001); panobinostat: DKO (**P = 0.0024), WT+mC3-BaxS184A (**P = 0.0010), WT+mC3-BaxS184E (*P = 0.0145), DKO+mC3-BaxS184E (**P = 0.0030);
STS: DKO (****P < 0.0001), WT+mC3-BaxS184E (**P = 0.0057), DKO+mC3-BaxS184E (****P < 0.0001)
C, D The indicated cell lines (left) were treated with 50 nM STS and 10 lM of caspase inhibitor (Q-VD-OPH) for 24 h, stained with DRAQ5 and MitoTracker Red (mtR).
Untransfected Bax/ Bak/ DKO BMK cells (top panel) were stained with MitoTracker Green (mtG) as a positive control for co-localization with MitoTracker Red.
Cells were imaged using an Opera Phenix automated confocal microscope (C, representative images; and D, co-localization analysis). (C) Representative images
(63× water-immersion objective) of cells treated with caspase inhibitor (10 lM Q-VD-OPH) and either DMSO or 50 nM STS are shown. Images shown are cropped,
highlighting single cells to aid in visual discrimination of localization. Scale bars: 20 lm. (D) Cells were imaged as above, and the Pearson’s correlation coefficient
between the MitoTracker Red channel and the indicated channel below was calculated for each cell. Symbols indicate the mean Pearson’s correlation coefficient
per cell for each of eight technical replicates (> 50 cells per technical replicate). Bars indicated the mean Pearson’s correlation coefficient per cell across two
independent experiments (n = 2). The data were heteroscedastic; therefore, a one-way Welch’s ANOVA was used followed by post hoc Welch’s t-tests with
Bonferroni correction. Comparisons were made between DMSO control and STS within each group: mC3-Bax (****P < 0.0001); mC3-Bax S184E (****P < 0.0001);
mC3-BaxS184A (ns = not significant).
Data information: See also Fig EV4.
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cancers that have BAX amplifications tend to have upregulated Akt
either by Akt pathway amplifications or PTEN deletions.
Amplification of the Akt pathway may permit, but not directly
result in, the overexpression of Bax. However, due to the anti-onco-
genic nature of Bax, we hypothesized that overexpression of Bax in
cancer requires its inhibition and that upregulation of the Akt path-
way could be a major mechanism. Thus, we examined associations of
both BAX and BAK1 CNA gain and mRNA overexpression in relation
to Akt pathway genes from the TCGA database (Figs 6C and EV5B;
Appendix Table S3). BAK1 was used as a control for BAX specificity,
since Bax and Bak are functionally redundant, if there is a specific link
between Bax and Akt, there may not be one with Bak. Associations
were examined in the pan-cancer (Fig 6C, Appendix Table S3) and in
breast invasive carcinoma (Fig EV5B, Appendix Table S3) samples as
an example from a single cancer type. The latter was chosen since five
of the seven cell lines studied here are breast cancer cell lines and it is
A
C
D
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a relatively data rich set. In breast invasive carcinoma, we observe
similar trends to that of the pan-cancer dataset. However, fewer of the
associations are statistically significant, a likely consequence of the
smaller size of this dataset.
As expected from the results obtained with data from cBioPortal,
BAX gain in the pan-cancer dataset was associated with gain of
AKT1, AKT2, and PIK3R1 and increased expression of AKT1 and
AKT2 mRNA (Fig 6C, Appendix Table S3). Furthermore, high BAX
mRNA expression is associated with an increase in AKT1 and AKT2
and a decrease in PTEN mRNA (Fig 6C, Appendix Table S3). Akt
directly targets Bax and thus the increased Akt is consistent with the
hypothesis that in cancers with high levels of Bax the protein is
phosphorylated and anti-apoptotic. However, contrary to our
hypothesis, there was a significant association between either BAX
gain or high BAX mRNA expression and decreased levels PIK3CA
and PIK3R1 mRNA (Appendix Table S3). As PI3K signaling is
upstream of Akt and regulates many pathways, there could be a
number of explanations for this observation. One possibility is that
low levels of PI3K activity due to lower expression of PI3K genes
could be countered by the decreased expression of PTEN that we
observe when BAX (CNA and mRNA) levels are high. As a control,
the same analysis was repeated for BAK1 (CNA and mRNA levels).
We found that, compared to BAX, there were more non-significant
associations between BAK1 and Akt pathway genes and of the
significant associations found the P-values were much higher
(Fig 6C, Appendix Table S3). The most significant association for
BAK1 was an increase in copy number for PTEN that was not seen
for BAX. Similar results were found in the breast invasive carcinoma
dataset (Fig EV5B, Appendix Table S3). These data suggest that
overall the BAX and AKT positive associations and the BAX and
PTEN negative associations are stronger compared to that of BAK1
and AKT or PTEN.
Due to the positive associations between increased BAX levels
and Akt pathway genes, we hypothesize a higher probability of
Akt pathway upregulation in patients with high BAX levels
compared to that with low BAX levels (Fig 6D). Probing the TCGA
database, 97.6% (200/205) of patients showing increase in BAX
copy number also show upregulation of the Akt pathway (defined
here as an increases in AKT1 OR AKT2 OR PIK3CA OR decrease
in PTEN copy number). This positive association is highly
significant when compared to the whole population (P = 7e-40).
On the other hand, only 58% (4,868/8,364) of patients where Bax
is neither increased nor decreased and 47% (93/198) of patients
showing a decrease in BAX copy number also show upregulation
of the Akt pathway. There was very little difference in the upregu-
lation of the Akt pathway in cancer patients with high or low
BAK1 levels (Fig 6D). When looking at breast invasive carcinoma,
the association of BAX levels and Akt pathway activation was
similar to the pan-cancer dataset (Fig EV5C). Thus, 97.5% (195/
200) of breast cancer patients showing increase in BAX copy
number also show upregulation of the Akt pathway compared to
50% (128/255) of patients where BAX is neither increased or
decreased and 58% (291/502) of breast cancer patients with low
BAX (P = 2e-36). The difference in Akt pathway activation
between low and high BAK1 copy number in breast cancer
patients is smaller than that found with BAX (Fig EV5C). Overall,
these results suggest that BAX copy number is strongly associated
with Akt pathway upregulation compared to BAK1, both in pan-
cancer and breast cancer patients. Taken together, the bioinfor-
matics data suggest that in tumors with elevated BAX the protein
may be phosphorylated and therefore anti-apoptotic due to upreg-
ulation of the Akt pathway.
Discussion
Residue S184 on Bax was reported to control Bax activation based on
a series of point mutations at S184 that were found to alter Bax pro-
apoptotic function [35]. Akt has also been shown to phosphorylate
Bax at S184 thereby inhibiting activation and mitochondrial localiza-
tion in response to various perturbations in several normal tissues,
including neutrophils and endothelial cells [15,19,36]. Activation of
Akt and phosphorylation of Bax at S184 are induced by nicotine in
lung cancer cell lines where it protects cells from cisplatin [16].
However, a recent study also reported that either co-expression of
Bax and Akt or expression of S184D phosphomimetic Bax results in
the activation of Bax [17]. Here, we have confirmed that Akt phos-
phorylates Bax at position S184 (Fig 3) and that both Akt phosphory-
lated and phosphomimetic Bax are defective in mediating membrane
permeabilization in multiple in vitro systems using isolated
◀ Figure 6. S184-phosphorylated Bax is correlated with ABT-737 resistance in primary ovarian cancer cells, while overexpression of Bax is countered by Aktpathway activation in human cancers.
A S184-phosphorylated Bax is correlated with ABT-737 resistance in primary ovarian cancer cells. Phosphorylation of Bax S184 was evaluated using lysates from the
indicated primary ovarian cancer cells by Western blotting with the indicated antibodies (IB) after immunoprecipitation with the indicated antibodies (IP) (left panel).
5–10% of the total lysates (input) were probed for Bax (Bax Δ21 antibody) and actin as expression and loading controls, respectively, by Western blotting with the
indicated antibodies (IB).
B To evaluate apoptotic response in primary ovarian cancer cells, cells from each OvCa cell line indicated in Fig 6A were treated with either carboplatin (100 lM), etoposide
(50 lM), paclitaxel (0.1 lM), and ABT-737 (0.5 lM) for 48 h, and apoptotic cells were evaluated by Annexin V/PI staining and flow cytometry (right panel). Apoptotic
response to each drug was plotted against the pBaxS184/Bax ratio (calculated from Fig 6A) for each primary ovarian cancer sample. Correlation between pBaxS184 and
response to drug treatment was evaluated two-tailed Spearman correlation. Only ABT-737 resistance was significantly (P < 0.05) correlated with pBax S184 levels.
Symbols indicate the mean of two experimental repeats (n = 2), each having two technical repeats for each of the seven OvCa cell lines treated with the indicated drug.
C TCGA database of all human cancers was probed for significant associations between the row heading (e.g., BAX CNA gain) and copy number (CNA) gain/loss (red/
blue) or mRNA up/downregulation (red/blue) of the indicated genes (AKT1, AKT2, and PTEN). Association strength is proportional to log(P-value), reflected in the radii
of the circles. Black circles indicates non-significant association (P-value cutoff = 0.02). The data used to generate this figure are located in Appendix Table S3.
D Each circle represents the total number of patients, across all cancers in the TCGA database, with either high BAX or BAK1 (higher than the mean, left) or low BAX or
BAK1 (lower than the mean, right) copy number. Within each circle, the proportion of patients with upregulated Akt pathway (red) is compared to the proportion of
patients without upregulated Akt pathway (blue). Upregulated Akt pathway is defined as an increase in AKT1 or AKT2 or PIK3CA or decrease in PTEN copy number.
Data information: See also Fig EV5.
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mitochondria (Fig 3), liposomes (Fig 4), mammalian cells (Fig 5),
and primary patient samples (Fig 6). Although we cannot rule out or
account for the localization or post-translational modifications of
other Bcl-2 family proteins in our experimental assays, our data
strongly suggest that the Akt target responsible for unpriming
mitochondria is Bax and not another mitochondrial protein, since
incubation of mitochondria with Akt and Bax, but not the phosphory-
lation-resistant mutant Bax S184A, prevents cytochrome c release
(Fig 3E–G).
Although previous studies correlated Bax inactivation and S184
phosphorylation, the mechanism remained unclear [15,18]. Previous
results were interpreted as suggesting that S184 phosphorylation of
Bax abrogated all steps in the Bax activation pathway (Fig 4A)
[15,16,19]. By assaying each step in the Bax activation pathway indi-
vidually, we identified that insertion of Bax into membranes is inhib-
ited by this post-translational modification. Subsequent steps
including Bax homo-oligomerization and pore formation were also
prevented suggesting the temporal order identified previously [28]
results from each step being dependent on successful completion of
the one before it. Since BH3 protein binding by Bax occurs at the
membrane but before insertion of Bax into membranes, it is logical
that some Bax S184E bound to activator BH3 proteins at membranes.
This is further supported by subcellular fractionation (Fig EV1C)
experiments under normal conditions and co-localization assays
(Figs 5D and EV4E) under apoptotic conditions showing some Bax
S184E at the mitochondria, albeit less than that of WT Bax or Bax
S184A. BH3 protein binding in solution was unexpected because
when Bax is in solution the BH3 binding site is normally occluded by
helix 9 and as a result, binding was not detected for Bax and BH3
proteins in the absence of membranes [28]. We speculate that the
addition of a negative charge within the hydrophobic groove by helix
9 by phosphorylation or mutation reduces the affinity of the helix 9
interaction and “opens” the BH3 binding site on Bax allowing BH3
activator binding in solution. Conversely, since Bax S184A sponta-
neously targets membranes but does not interact with cBid in solu-
tion, we speculate that helix 9 of the S184A mutant occludes the
hydrophobic groove in solution and only once a membrane is
present can helix 9 disengage allowing BH3 binding.
A phosphorylated Bax that does not permeabilize membranes yet
binds activator BH3 proteins inhibits MOMP by sequestering the
Figure 7. Phosphorylated Bax protects cells from apoptosis.
Cartoon showing how phosphorylation by Akt switches Bax activity from pro- to anti-apoptotic. (1) In cells without upregulated Akt signaling, cells are sensitive to pro-
apoptotic signaling and BH3mimetics (purple pentagon), and mitochondria are primed for death due to anti-apoptotic proteins (AA, red) like Bcl-XL, Bcl-2, and Mcl-1, binding
activator BH3 proteins (BH3, orange) like tBid and Bim, at the mitochondrial outer membrane. Pro-apoptotic signaling or addition of a BH3mimetic such as ABT-737 displaces
activator BH3 proteins from anti-apoptotic proteins, whereupon tBid or Bim activates Bax (green) leading to MOMP and cell death. (2) In cells with upregulated Akt signaling,
cells are resistant to pro-apoptotic signaling and BH3mimetics (purple pentagon) because Bax is phosphorylated (P, yellow) at position S184 by Akt. Phosphorylation prevents
Bax inserting into the mitochondrial outer membrane while allowing activator BH3 binding. Cells become resistant to BH3mimetics and pro-apoptotic BH3 proteins, because
activator BH3 proteins released from anti-apoptotic proteins are sequestered by phosphorylated Baxmainly in the cytosol but also peripherally at mitochondria via binding of
BH3 proteins inserted into the bilayer. Sequestration by Bax prevents BH3 proteins from activating non-phosphorylated Bax and Bak.
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BH3 protein similar to mode 1 inhibition of BH3 proteins by anti-
apoptotic Bcl-2 family proteins [30,31]. As phosphomimetic Bax
competitively sequesters activator BH3 proteins, but does not bind
WT Bax (Fig 4), it is expected to be less effective at inhibiting apop-
tosis than anti-apoptotic Bcl-2 proteins. Thus, phosphorylation of
Bax by Akt converts Bax from pro- to anti-apoptotic, resulting in a
diminished sensitivity of mitochondria to apoptotic signaling by
BH3 proteins. As a consequence, cancer cell lines and primary
patient cells are resistant to drugs that activate apoptosis, including
the Bcl-2/Bcl-XL/Bcl-w antagonist ABT-737 (Figs 1B and 6A).
Consistent with this conclusion, expression of Bax S184E in cells
with endogenous Bax and Bak protected cells from apoptotic stimuli
while having a predominately cytosolic localization suggesting that
phosphorylated Bax likely sequesters activator BH3 proteins in the
cytoplasm (Fig 5B–D). However, some Bax S184E did target to mito-
chondria under apoptotic conditions; thus, Bax S184E and S184-
phosphorylated Bax may inhibit BH3 proteins at the mitochondria
as well.
In primary patient samples, the amount of S184-phosphory-
lated Bax directly correlates with resistance to BH3 mimetics
(Fig 6A and B). A predicted consequence of inhibition of apopto-
sis by phosphorylated Bax is that Bax phosphorylation in cells by
upregulated Akt likely provides a selective advantage for cancer
cells that have increased levels of Bax. As a tumor suppressor,
Bax expression is usually decreased in cancer cells. Indeed, over-
expression of Bax sensitizes cancer cells to apoptosis induced by
chemotherapy or radiation [37–41] and can be correlated with
improved clinical outcomes in ovarian cancer and gastric cancer
[42,43]. However, in other cancers, high Bax expression is associ-
ated with poorer outcomes and an increased risk of relapse [44–
46]. Our analysis clearly demonstrates that when Bax copy
number is increased, 97.6% of the patients also show upregula-
tion of the Akt pathway (Fig 6D), suggesting the latter observa-
tion may be more prevalent. Phosphorylation of Bax by Akt
provides an explanation for these observations as S184-phos-
phorylated Bax would allow cells to evade apoptosis by compet-
ing with WT Bax and Bak for binding to BH3 proteins (Fig 7).
Furthermore, phosphorylated Bax may have a binding advantage
for BH3 proteins since phosphomimetic Bax binds to activator
BH3 proteins in solution and at membranes, whereas WT Bax
and Bak only bind membrane bound activator BH3 proteins.
Thus, increased expression of Bax in cells with upregulated Akt
represents a novel mechanism for cancer cells to prevent apopto-
sis and acquire drug resistance.
Our findings are of clinical importance because activation of
the Akt pathway occurs often in cancer cells as a result of loss of
PTEN, aberrant receptor tyrosine kinase activity or PIK3CA or
AKT1 activating mutations. This heterogeneity has made it diffi-
cult to establish predictive biomarkers. An important role for Bax
phosphorylation in the anti-apoptotic effects of Akt as elucidated
here suggests that phosphorylation of Bax at S184 is a potential
predictive, and perhaps pharmacodynamic, biomarker for pharma-
cologic inhibitors of the Akt pathway in cancer clinical trials.
Intriguingly, Choudhary et al [23] showed that non-Hodgkin
lymphoma cell lines with acquired resistance to ABT-199 had
substantial Akt activation. These cells became sensitive to ABT-
199 only after treatment with dual AKT/mTOR pathway inhibi-
tors. Although this group did not look at the phosphorylation
status of Bax, we would predict that acquired resistance to ABT-
199 in these cells was due in part to the anti-apoptotic effects of
phosphorylated Bax. Considering the growing interest in BH3
mimetics as anti-cancer agents, and the ongoing development of
Akt pathway inhibitors, we suggest that examination of possible
combinatorial therapies for cancers with upregulated Akt is
warranted.
Materials and Methods
Antibodies, reagents, and plasmids
Antibodies
Akt (#9272), Actin (#4967), Bax (#2772), Bak (#3814), and GAPDH
(#2118) were from Cell Signaling. Cytochrome c (7H8.2C12) was
from BD Biosciences. Phosphoserine (4A9; #525284) was purchased
from EMD Millipore. b-Actin (#Y00005-002) was from Immune
Biosolutions (used in Fig EV4B). GFP (19F7) was from Memorial
Sloan-Kettering Monoclonal Antibody Facility. Bax Δ21 antibody
(#sc-6236) was from Santa Cruz. pBax S184 antibody (ab111391)
was from Abcam.
Reagents
ABT-737, negative control enantiomer, and A-443654 were obtained
from Abbott Laboratories. MK-2206 and LY294002 were purchased
from Selleck Chemicals. Deguelin was obtained from Tocris
Bioscience, Minneapolis. Recombinant Human Active Akt1 was
obtained from R&D Systems (1775-KS) and Sigma (A8729).
Plasmids
GFP-Bax (hBax C3-EGFP, Addgene plasmid 19741), GFP-Bax S184A
(hBax S184A C3-EGFP, Addgene plasmid 19742), and GFP-Bax
S184E (hBax S184E C3-EGFP, Addgene plasmid 19743) were previ-
ously described [35]. GFP (PCDNA3-EGFP, Addgene plasmid 13031)
was used as a control for transfections. Single cysteine Bax 126C
(pMAC1731) and single cysteine cBid 126C (pMAC2118) were previ-
ously described [28]. The cDNA for single cysteine Bax 175C was
transferred from the corresponding retroviral vector [29] into the
IMPACT expression system (New England Biolabs, Ipswich, MA,
USA) generating pMAC 1739. Bax S184E and S184A mutation was
introduced into the Bax WT, Bax 126C, and Bax 175C plasmids via
QuikChangeTM mutagenesis (Stratagene).
The cDNA from a plasmid encoding mCerulean3 protein [47]
was put in place of the EGFP coding region in pEGFP-C1 (Clon-
tech). The plasmid encoding mCerulean3 was a gift from Mark
Rizzo (University of Maryland School of Medicine), and the
pEGFP-C1 plasmid was a gift from Ray Truant (McMaster Univer-
sity). To generate a plasmid containing mCerulean3-Bax S184E,
the cDNA of Bax-a was amplified by PCR and inserted after the
mCerulean3 coding region. The entire coding region of mCeru-
lean3-Bax was cut out from this plasmid and inserted into the
MCS1 of pVitro2-Blasti-MCS (Invivogen plasmid pvitro2-bmcs)
that was shortened to remove one of the two gene expression
elements (CMV Enhancer, hFerL promoter, chEF1 5’UTR, and
MCS2). Site-directed mutagenesis was used on this construct as
above to generate mCerulean3-BaxS184E and mCerulean3-
BaxS184A plasmids.
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Cell culture
MDA-MB-435, MCF-7, T47-D, MDA-MB-468, ZR-75-1, and SF539
AND 768-O cells were grown in DMEM/F12 (Invitrogen), and WT
MEFs and Bax/ Bak/ DKO MEFs were grown in DMEM (Invit-
rogen) supplemented with 2 mM L-glutamine, 10% heat-inactivated
fetal bovine serum (Sigma), 100 IU/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen) in a humidified incubator at 37°C and 5%
CO2. MDA-MB-468 cells were stably transfected with vectors
containing GFP, GFP-Bax, GFP-Bax S184A, and GFP-Bax S184E plas-
mids using FuGENE 6 (Roche), and the clonal selection was carried
out in the presence of G418 (1.2–1.6 mg/ml, Sigma). Selected clones
were maintained in growth medium containing 0.16 mg/ml G418.
WT baby mouse kidney (BMK) cells and their Bax/ Bak/
DKO derivative were gifts from Eileen White (Rutgers University).
The WT and Bax/ Bak/ DKO BMK cells were cultured in DMEM
supplemented with 10% FBS and 1% MEM NEAA. WT BMK cells
were stably transfected with a vector encoding mCerulean3-Bax-
S184E using FuGENE HD (Roche), and clonal selection was carried
out in the presence of 5 lg/ml blasticidin (BLA477; Bioshop). WT
BMK cells stably transfected with a plasmid encoding mCerulean3-
Bax-S184E were subjected to two rounds of fluorescence-activated
cell sorting to isolate cells stably expressing mCerulean3-BaxS184E.
Immunoblotting, immunoprecipitation, and
coimmunoprecipitation
Total cell lysates were prepared in 1% CHAPS buffer [5 mM MgCl2,
137 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% CHAPS, 20 mM Tris–
HCl (pH 7.5), protease inhibitors (Complete, Roche), and phos-
phatase inhibitors (PhosSTOP; Roche)] as reported previously [48].
For coimmunoprecipitations, proteins (800 lg–10 mg) were
immunoprecipitated with indicated antibodies at 4°C for 2 h or O/
N, and coimmunoprecipitates were captured by Dynabeads Protein
G at 4°C for 2 h or O/N. Beads were recovered using DynaMag Spin
Magnet and washed thrice in 1% CHAPS buffer. For Bax immuno-
precipitations for phosphorylation analysis, proteins were isolated
in a modified RIPA buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
1% NP-40, 0.5% Na-deoxycholate, 1 mM EDTA, 1 mM EGTA,
1 mM PMSF, protease inhibitors (Complete; Roche), and phos-
phatase inhibitors (PhosSTOP; Roche)] and immunoprecipitated
with Bax Δ21 antibody (#sc-6236; Santa Cruz). Immunoprecipitates,
total cell extracts, and subfractionation lysates were separated on
NuPAGE 10% Bis-Tris gels. Following SDS–PAGE, proteins were
transferred onto PVDF membranes (Immobilon) and then blocked
with 5% dried milk in PBS–Tween-20. Membranes were incubated
with a 1:1,000 dilution of primary antibodies (as indicated and
described above) and 1:5,000 dilution of secondary antibodies (GE
Healthcare Life Sciences), in a buffer containing 10% milk diluent
blocking concentrate (KPL), and detected with SuperSignal West
Pico Chemiluminescent Substrate (Thermo Fisher Scientific). For
phosphorylation blots, 4% BSA in TBS–Tween was used for block-
ing and antibody preparation and TBS–Tween was used for
membrane washing steps. Blots were imaged with LAS4000 image
analyzer (Fujifilm) on chemiluminescence mode.
For blots in Fig EV4B, cells were harvested and washed in ice-
cold PBS, pelleted, and resuspended in 1 ml cell lysis buffer [1%
Triton X-100, 150 nM NaCl, 10 mM Tris (pH 8.0)], heated for 5 min
at 98°C, and pelleted. Whole-cell lysate protein concentration was
quantified by Bradford (Bio-Rad Protein Assay) and standardized to
1 mg/ml. Whole-cell lysate proteins (15 lg per lane) were separated
by SDS–PAGE, and Bax, Bak, and Actin were detected by
immunoblotting. Primary antibodies were used at 1:1,000 dilution
for Bax (Rabbit-a-Bax, #2772; Cell Signaling), Bak (Rabbit-a-Bak,
#3814, Cell Signaling), and b-actin (Chicken-a-b-actin, #Y00005-002,
Immune Biosolutions). Secondary antibodies were used at a
1:20,000 dilution from Jackson ImmunoResearch Inc. (for Bax and
Bak; Donkey-a-Rabbit, #711-035-152) and Immune Biosolutions (for
b-actin; Aurora Alpaca-a-Chicken, #Y00008-HRP). Immunoblots
were developed using chemiluminescence, and intensities were
recorded using a CCD camera (DNR).
Peptide synthesis
Peptides were synthesized by Tufts University Core Facility and
purified by HPLC. Peptide identities were confirmed by mass spec-
trometry, and stock solutions were prepared in DMSO. tBid gener-
ated from His-tagged human Bid cleaved with recombinant caspase-8
was a generous gift from Claudio Hetz (University of Chile,
Santiago, Chile).
Phosphoprotein gel staining
Protein samples after kinase reactions were separated on 10% Bis-
Tris NuPAGE gels and stained with Pro-Q Diamond phosphoprotein
gel stain and SYPRO Ruby total protein gel stain (Invitrogen) accord-
ing to manufacturer’s protocol. Gels were imaged with LAS4000
image analyzer (Fujifilm), using the same exposure settings for dif-
ferent samples on green and blue fluorescence epi-illumination
mode, and the quantitation of bands was performed using ImageJ
software.
Protein purification and labeling, and liposome preparation
WT and single cysteine Bax mutants, 126C and 175C with or with-
out the S184E or S184A mutation, were expressed, purified, and
labeled (when indicated) with DAC or NBD, as previously described
[27]. Single cysteine His-Bid 126C was expressed, purified, and
labeled with DAC as previously described [27]. Liposomes were
prepared as previously published [27]. Briefly, a 1 mg mitochon-
dria-like lipid film [0.46 mg of egg phosphatidylcholine (PC),
0.25 mg of egg phosphatidylethanolamine (PE), 0.11 mg of bovine
liver phosphatidylinositol (PI), 0.10 mg 18:1 dioleoyl phos-
phatidylserine (DOPS), and 0.08 mg tetraoleoyl cardiolipin (TOCL)]
was hydrated 1 with ml of assay buffer (10 mM HEPES pH 7.2,
200 mM KCl, 1 mM MgCl2; all lipids were acquired from Avanti
Polar Lipids). Hydrated lipid films underwent 10 freeze-thaw cycles
and were extruded 11 times through a 100-nm-pore-size nucleopore
track-etched polycarbonate membrane (Whatman).
Subcellular fractionation
Subcellular fractionation was performed as reported before [49].
Briefly, cells were harvested and washed in ice-cold PBS and then
resuspended in an isotonic buffer [250 mM sucrose, 20 mM HEPES
(pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA,
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1 mM PMSF, and protease inhibitors (Complete, Roche)] on ice for
20 min. Phosphatase inhibitors (PhosSTOP; Roche) were added as
indicated. After incubation, cells were homogenized with Dounce
homogenizer and centrifuged at 800 g for 10 min at 4°C. The
remaining supernatant was centrifuged at 8,000 g for 20 min at 4°C
to obtain mitochondria-enriched HM pellet and cytosolic fractions.
To obtain S-100 fractions, the remaining supernatant (cytosolic frac-
tion) was further centrifuged at 100,000 g for 1 h at 4°C. The result-
ing pellet constituted LM and the supernatant was saved as S-100.
Mitochondria-enriched pellets were lysed in 1% CHAPS buffer for
immunoblot analysis.
Nuclear protein isolation
Cells were washed with ice-cold phosphate-buffered saline (PBS)
and harvested by centrifugation. Cells were lysed by incubation for
10 min in cold hypotonic buffer [10 mM HEPES/KOH (pH 7.9),
10 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 0.5 mM
PMSF, protease inhibitors, and Nonidet P-40 (0.2%)]. After centrifu-
gation at 15,000 g for 30 s, supernatants containing cytoplasmic
proteins were removed. Nuclear protein isolation was carried out by
incubation of the pellet for 20 min on ice in a cold saline buffer
[20 mM HEPES/KOH (pH 7.9), 1.5 mM MgCl2, 0.2 mM EDTA,
650 mM NaCl, glycerol (25%, v/v), 1 mM DTT, 0.5 mM PMSF, and
protease inhibitors]. After centrifugation at 15,000 g for 20 min at
4°C, supernatants were stored as nuclear proteins. GAPDH was used
as cytosolic marker, and COXIV was used as mitochondrial marker
for immunoblots.
BH3 profiling
BH3 profiling assays and peptide sequences were previously reported
[6,20]. Briefly, 0.5 mg of protein/ml mitochondria was suspended in
mitochondria buffer (125 mM KCl, 10 mM Tris–MOPS, pH 7.4, 5 mM
glutamate, 2.5 mM malate, 1 mM KPO4, and 10 lM EGTA–Tris, pH
7.4) and exposed to BH3 peptides (100 lM) for 40 min at room
temperature. Phosphatase inhibitors (PhosSTOP) were added as indi-
cated in the figures to the mitochondria buffer. Cytochrome c release
was calculated by dividing the amount of cytochrome c detected in
the supernatant fraction by the total amount of cytochrome c in the
supernatant and pellet fractions. The amount of cytochrome c in each
fraction was determined by ELISA (#SCTC0; R&D Systems) and
expressed as % of untreated control. For BH3 experiments using
mitochondria treated with S100 fractions, S100 fractions were
immunodepleted for Akt by sequential immunoprecipitations using
anti-Akt antibody (Cell Signaling, #9272) and Dynabeads twice. IgG
immunoprecipitations were done in parallel as a negative control.
Mitochondria were incubated with immunodepleted S100 fractions
for 1 h at 30°C, washed twice with mitochondria buffer containing
PhosSTOP, and incubated with BH3 peptides for 40 min at room
temperature. Cytochrome c release was determined by ELISA, as
above. For BH3 experiments using mitochondria treated with recom-
binant active Akt, mitochondria (0.1 mg/ml) were incubated with
recombinant active Akt (1 lg) and ATP (400 lM) for 1 h in kinase
assay buffer [25 mM Tris–HCl (pH 7.5), 5 mM beta-glyceropho-
sphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10 mM MgCl2]
for 2 h at 30°C, washed twice with mitochondria buffer containing
PhosSTOP, and treated with BH3 peptides for 40 min at room temper-
ature. Cytochrome c release was determined by ELISA, as above.
Mitochondrial permeabilization assay
Mitochondria were purified from Bax/ Bak/ DKO MEFs and
resuspended in mitochondria buffer (0.5 mg of protein/ml mito-
chondria) and incubated with tBid and Bax for 1 h at room tempera-
ture. tBid and Bax were pre-incubated with recombinant active Akt
(400 ng) and ATP (200 lM) in kinase assay buffer for 2 h at 30°C
as indicated some experiments. Pre-incubation with 120 nM MK-
2206 for 1 h was used to block Akt kinase activity as indicated.
Cytochrome c release was determined by ELISA, as above.
Apoptosis and cell viability assays
Cell proliferation kit (MTT; Roche) and alamar blue (Invitrogen)
were used to determine cell viability and survival of cells as
described by the manufacturer. For Fig 2D, apoptosis was evaluated
by Annexin V–FITC and Annexin V–Cy3 (BioVision) staining using
a FACSCanto (BD Biosciences) flow cytometer and WinMDI 2.9 soft-
ware (Scripps Institute).
Confocal microscopy
For Fig 2C, GFP-tagged protein-expressing cells were grown in Lab-
Tek II chamber slides (Thermo Fisher Scientific) and co-stained with
MitoTracker Red CMXRos (Molecular Probes, Invitrogen) before fix-
ation in 4% PFA. Monolayer cells fixed with 4% paraformaldehyde
were mounted with Vectashield mounting medium with DAPI (Vec-
tor Laboratories). Cells were imaged by using spinning disk confocal
microscope (Yokogawa) using an Andor iXon EM-CCD camera with
a 40× oil objective. Three channels were captured: (i) DAPI (excita-
tion laser: 405 nm; emission filter: 455/50 nm bandpass); (ii) Alexa
488 (excitation laser: 488 nm; emission filter: 525/36 nm band-
pass); and (iii) MitoTracker Red (excitation laser: 561 nm; emission
filter: 605/52 nm bandpass). Images were pseudo-colored and
analyzed by using ImageJ software. Co-localization analysis for
GFP-Bax image was performed using CoLocalizer Pro software for
Mac (3.0.2). Pearson’s correlation coefficient was used to evaluate
the co-localization of GFP-Bax and MitoTracker channels.
Live cell imaging and analysis
WT BMK cells, WT BMK cells with a stable expression of mCeru-
lean3-Bax-S184E or Bax mCerulean3-Bax-S184A, Bax/ Bak/
DKO BMK cells, or Bax/ Bak/ DKO BMK cells with a stable
expression of mCerulean3-Bax, mCerulean3-Bax-S184E, or mCeru-
lean3-Bax-S184A were seeded at ~2,000 cells/well in a 384-well
imaging plate (PerkinElmer Cell Carrier Ultra). Twenty hours later,
cells were incubated with indicated concentrations of TNF-a
(S0419041; Invitrogen), staurosporine (S5921; Sigma-Aldrich),
panobinostat (A10518; Adooq Bioscience), or DMSO (as a negative
control) for 20 h. Where indicated, the cells were also treated with
10 lM caspase inhibitor Q-OVD-OPH (03OPH10903; MP Biomedi-
cals) for the 20-h incubation.
For Figs 5B and EV4C: 30 min prior to imaging, cells were co-
stained with 5 lM DRAQ5 (Biostatus), a 1/1,000 dilution of TMRE
(Life technologies) and 1/1,000 dilution of Annexin V conjugated to
Alexa 488 which was prepared in our laboratory and used as
described previously [50]. DRAQ5 staining was used to identify all
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cells, TMRE, a dye that is only fluorescent at mitochondria when
there is a membrane potential, was used to measure loss of mito-
chondria membrane potential, and Annexin V–Alexa 488 staining
was used to identify apoptotic cells. Cells were imaged using an
Opera Phenix automated confocal microscope (PerkinElmer) with a
20× air objective. Four channels were captured: (i) DRAQ5 (excita-
tion laser: 640 nm; emission filter: 650–760 nm); (ii) Annexin V–
Alexa 488 (excitation laser: 488 nm; emission filter: 500–550); (iii)
TMRE (excitation laser: 561 nm; emission filter: 570–630 nm); and
(iv) mCerulean3 (excitation laser: 425 nm; emission filter: 435–
550 nm). Image acquisition, calculation of intensity features for
each channel, and image analysis were performed using Harmony
software (PerkinElmer). The DRAQ5 channel was used identify the
nucleus and cytoplasm of each cell. TMRE-negative cells were
assigned based on a per-cell cytoplasmic TMRE intensity less than a
threshold of 2 standard deviations above the per-cell cytoplasmic
TMRE intensity in 100 nM STS-treated WT BMK cells (our cell death
positive control). Annexin V–Alexa 488-positive cells were assigned
based on a per-cell Alexa 488 intensity greater than a threshold of 2
standard deviations above the per-cell Annexin V–Alexa 488 inten-
sity of untreated DMSO controls. The percentage of apoptosis was
calculated by taking the total number of TMRE-negative and
Annexin V–Alexa 488-positive cells dividing by the total number of
cells imaged under each condition. Two technical replicates were
performed for each of four independent experiments (n = 4). Each
technical replicate was in a separate well, and a minimum of five
different fields of view (~50 cells per field) were acquired.
For Fig 5C and D: After 20-h treatment with caspase inhibitor
and either STS or DMSO, cells were co-stained with 5 lM DRAQ5
(to visualize the nucleus) and 1/1,000 dilution of MitoTracker Red
CMXRos 30 min before imaging. Where indicated, the cells were
also stained with a 1/1,000 dilution of MitoTracker Green. Cells
were imaged on the Opera Phenix automated confocal microscope
(PerkinElmer) with water-immersion objectives at 63× (for represen-
tative images, Fig 5C) and 40× (for image analysis, Fig 5D). Three
channels were captured: (i) DRAQ5 (excitation laser: 640 nm; emis-
sion filter: 650–760 nm); (ii) MitoTracker Red (excitation laser:
561 nm; emission filter: 570–630); and (iii) mCerulean3/Mito-
Tracker Green (excitation laser: 425 nm; emission filter: 435–550).
Image acquisition, calculation of intensity features for each channel,
and image analysis were performed using Harmony software (Perki-
nElmer). The DRAQ5 channel was used to identify the nucleus and
the cytoplasm of each cell. The average per-cell Pearson’s correla-
tion coefficient between the MitoTracker Red and either MitoTracker
Green (positive control for co-localization to mitochondria) or mCer-
ulean3 in the cytoplasm was calculated using built in co-localization
analysis in Harmony software. Four technical replicates were
performed for each of two independent experiments (n = 2). Each
technical replicate was in a separate well, and a minimum of 15 dif-
ferent fields of view (50 cells per field) were acquired.
For Fig EV4D and E: After 20-h treatment with caspase inhibitor
and either STS or DMSO, cells were stained with 5 lM DRAQ5 (to
visualize the nucleus) 30 min before imaging on the Opera Phenix
automated confocal microscope (PerkinElmer) with water-immer-
sion objectives at 63× (for representative images, Fig EV4D) and
40× (for image analysis, Fig EV4E). Two channels were captured:
(i) DRAQ5 (excitation laser: 640 nm; emission filter: 650–760 nm);
and (ii) mCerulean3 (excitation laser: 425 nm; emission filter: 435–
550). Image acquisition, calculation of intensity features for each
channel, and image analysis were performed using Harmony soft-
ware (PerkinElmer). The DRAQ5 channel was used to identify the
nucleus and the cytoplasm of each cell. Both the average and stan-
dard deviation of the mCerulean3 intensity in the cytoplasm were
calculated for each cell. Diffuse and punctate localization patterns
have a lower and higher, respectively, per-cell standard deviation of
fluorescence intensity. To identify cells with a punctate localization
pattern, the standard deviation in mCerulean3 fluorescence was
calculated for all imaged cells. A cell was assigned a punctate local-
ization pattern if the standard deviation of mCerulean3 fluorescence
was more than two standard deviations higher than the average
standard deviation of mCerulean3 intensity in DMSO-treated control
cells. The percentage of punctate cells was calculated by taking the
total number of cells identified as punctate and dividing by the total
number of cells identified. Two technical replicates were performed
for each of three independent experiments (n = 3). Each technical
replicate was in a separate well, and a minimum of 15 different
fields of view (50 cells per field) were acquired.
Bax membrane permeabilization: ANTS/DPX release assay
For membrane permeabilization assays, a mitochondria-like lipid
film was hydrated with 1 ml of assay buffer supplemented with
12.5 mM of the fluorophore 8-aminonaphthalene-1,3,6-trisulfonic
acid (ANTS) and 45 mM of the quencher p-xylene-bis-pyridinium
bromide (DPX; Molecular Probes). Liposomes were prepared as
above and after extrusion, and unencapsulated ANTS and DPX were
removed by passing the liposomes over a 10-ml CL2B gel-filtration
column (GE Healthcare Life Sciences). ANTS/DPX release assay was
performed as previously described [28,31]. Briefly, 8 ll of ANTS/
DPX encapsulated liposomes was added to a reaction of 100 ll final
volume in assay buffer. Fluorescence of ANTS (kex = 355 nm,
kem = 520 nm) was measured over the course of 2 h at 37°C.
Percent ANTS release was calculated as % release = [(Ffinal  F0)/
(F100  F0)]*100, where Ffinal is the fluorescence at a 2-h endpoint,
F0 is the fluorescence in the absence of proteins, and F100 is the fluo-
rescence of liposomes permeabilized with 0.2% v/v Triton X-100.
Fluorescence experiments: measuring protein–protein
interactions via FRET and Bax insertion into membranes
NBD emission assays and FRET experiments were performed as
previously described [28]. In a black 96-well half-area non-binding
surface assay plate (Corning #3881), 10 ll of 1 mg/ml mitochon-
dria-like liposomes was added to a reaction of 100 ll final volume
in assay buffer. Fluorescence emission of 100 nM Bax 175C-NBD
and Bax 175C-NBD S184E (kex = 475 nm, kem = 530 nm) incubated
with or without 20 nM recombinant cBid was recorded using a
Tecan Infinite M1000 plate reader (Tecan) at 2-h endpoint 37°C.
Relative change in NBD emission was expressed as F/F0 =
(Ffinal  Fbckg)/(Finitial  Fbckg), where Fbckg is the fluorescence
signal of liposomes and buffer, Finitial is the fluorescence signal once
NBD-labeled protein was added to the well, and Ffinal is the fluores-
cence signal at 1-h endpoint. cBid–Bax FRET was similarly
measured; however, the emission of cBid 126C-DAC donor
(kex = 380 nm, kem = 460 nm) was recorded. FRET efficiency was
calculated as % FRET efficiency = 1  [(FDA  Fbckg)/
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(FD  Fbckg)] × 100, where FDA is the fluorescence emission of
20 nM cBid 126C-DAC donor in the presence of 100 nM NBD-
labeled Bax acceptor at 2-h endpoint, FD is the fluorescence
emission of 20 nM cBid 126C-DAC donor alone in the presence of
unlabeled Bax 126C at 2-h endpoint, and Fbckg is the fluorescence
signal of liposomes and assay buffer alone. Bax–Bax FRET was
measured as cBid–Bax FRET; however, measurements were
recorded in a PTI QM-40 fluorometer (Photon Technology Interna-
tional), using a 1.8-ml quartz cuvette containing 100 ll lipids in a
final reaction volume of 1 ml in assay buffer at 37°C. FRET effi-
ciency was calculated as above; however, FDA is the fluorescence
emission of 10 nM DAC-labeled Bax donor in the presence of
100 nM NBD-labeled Bax acceptor at 2-h endpoint, and FD is the
fluorescence emission of 10 nM DAC-labeled Bax donor in the
presence of 100 nM unlabeled Bax acceptor.
For Fig 4B, the dissociation constant (KD) for the interaction
between cBid and Bax was extracted from the titration curve by fit-
ting the data to Equation 1 which models the FRET that occurs
between two interacting proteins. Here, we assume that the binding
between cBid (A) and Bax (B) is in equilibrium (Aþ B AB) [28].
Ffretð½BT Þ ¼
ðFmaxÞ
½AT  þ ½BT  þ KDð Þ 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
½AT  þ ½BT  þ KDð Þ24½AT ½BT 
q
2½AT 
0
@
1
A;
(1)
where Ffret([BT]) is a function describing the FRET efficiency at any
concentration of B. Fmax is the maximum FRET efficiency given
that all of A is bound to B. [AT] and [BT] are the total concentra-
tions of protein A and B, respectively, and KD is described by:
KD ¼ ½A½B½AB : (2)
In this case, [A], [B], and [AB] are the equilibrium concentrations
of cBid, Bax, and a cBid:Bax heterodimer, respectively, and [AT] and
[BT] are the total concentrations of cBid and Bax, respectively.
Ovarian cancer cells
Primary ovarian cancer cells were isolated as described before [51].
The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki, and it was approved by the ethics commit-
tee of Baskent University School of Medicine (KA15/230). Informed
consent was obtained from all participants.
Briefly, malignant ascites samples (20–50 ml) were collected
from ovarian cancer patients, and cells were pelleted, resuspended
in PBS, and separated on a discontinuous gradient consisting of
Lymphoprep (Axis-Shield, Norway), Lymphoprep/Krebs HEPES
Ring solution 3:1, and Lymphoprep/Krebs HEPES Ring solution 1:2
(Krebs HEPES Ring solution: 137 mM NaCl, 5.4 mM KCl, 0.34 mM
Na2HPO4, 0.35 mM KH2PO4, 8 mM MgSO4, 1 mM HEPES pH 7.4).
Cells were then centrifuged at 1,500 × g for 20 min, and tumor cells
were collected at the interphase between the top and middle layers,
washed, and plated. Cells were grown at 37°C in 5% CO2 in RPMI-
1640 medium supplemented with 10% FCS and 1% Pen/Strep. All
patients were chemotherapy naı¨ve, FIGO stage IIIC, with a median
age of diagnosis at 61.2 years. Tumors were identified as serous
epithelial ovarian carcinoma.
To evaluate apoptotic response in ovarian cancer cells, cells were
treated with carboplatin (100 lM), etoposide (50 lM), paclitaxel
(100 nM), and ABT-737 (0.5 lM) for 48 h, and apoptotic cells were
evaluated by Annexin V/PI staining and flow cytometry.
pBAXS184/BAX ratio was determined by using Image Studio Digits
V3.1 software. Correlation of pBAXS184 level and response to drug
treatment in ovarian cancer cells was evaluated two-tailed Spear-
man correlation by using GraphPad 5.0 software.
Statistical analysis of in vitro data
GraphPad Prism 7.0 software (GraphPad Software, San Diego, CA,
USA) was used for data analysis and to determine the significance
of statistical differences between data. All data were assumed to
have a Gaussian distribution. Homoscedasticity (equal variance) of
the data was tested using the Brown–Forsythe test. If the data were
homoscedastic (passes the Brown–Forsythe test), then either a one-
way or two-way ANOVA (where indicated in figure legends) was
used followed by followed by post hoc unpaired t-tests (two-tailed
with a = 0.05) with Bonferroni correction for multiple comparisons.
Only in the case of Fig 5D, did the data fail the Brown–Forsythe test
and the data had unequal variances. In this case, Welch’s ANOVA
followed post hoc unpaired Welch’s t-tests (two-tailed with
a = 0.05) with Bonferroni correction for multiple comparisons were
used as these statistical tests do not assume homoscedastic data. All
P-values are multiplicity adjusted P-values calculated in GraphPad
Prism and are either listed in the figure legends or in
Appendix Tables S1 and S2. Symbols in figures indicate P-values:
ns (P > 0.05), *(P ≤ 0.05), **(P ≤ 0.01), ***(P ≤ 0.001), and ****
(P < 0.0001).
Bioinformatics analysis and statistics
CNA analysis
CNA data were obtained from cBioPortal [52,53]. Duplications and
deletions were defined as log2CNA > 0.5 or < 0.5, respectively.
Association with the Akt pathway was evaluated using a Cochran–
Armitage test for trend on the number of Akt pathway genes (AKT1,
AKT2, AKT3, PIK3CA, PIK3R1) that were duplicated in patients
carrying BAX or BAK duplications. Association with PTEN was eval-
uated using a Fisher’s exact test.
TCGA pan-cancer gene-level analysis
This analysis covered expression (n = 9,755), copy number
(n = 10,843), and mutation data (n = 6,901) across 42 cancers. Data
were obtained from the Cancer Browser [54]. This database uses the
software GISTIC2 [55] to normalize copy number gain or copy
number loss, which were defined in the present work as a GISTIC2
call ≥ 1 or ≤ 1, respectively. Gene expression association was evalu-
ated by ranking expression values of the reference gene and apply-
ing a two-tailed unpaired Student’s t-test to evaluate differential
gene expression between 1st and 10th deciles across genes. Bonfer-
roni correction was applied to determine the associations that were
significant (P-value cutoff of 0.02 was chosen arbitrarily). High and
low Bax copy numbers (Figs 6D and EV5C) were defined as the n
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patients with the top highest/lowest Bax GISTIC2 call. Upregulated
Akt pathway was defined as an increase in AKT1 or AKT2 or
PIK3CA or decrease in PTEN copy number.
Expanded View for this article is available online.
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